Nelson K, Fuster V, Ridker PM (August 2023). "Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease: JACC Review Topic of the Week". Journal of the American College of Cardiology. 82 (7): 648–660. doi:10.1016/j.jacc.2023.05.055. PMID37558377. S2CID260715494.
Cocco G, Chu DC, Pandolfi S (December 2010). "Colchicine in clinical medicine. A guide for internists". European Journal of Internal Medicine. 21 (6): 503–508. doi:10.1016/j.ejim.2010.09.010. PMID21111934.
Portincasa P (2016). "Colchicine, Biologic Agents and More for the Treatment of Familial Mediterranean Fever. The Old, the New, and the Rare". Current Medicinal Chemistry. 23 (1): 60–86. doi:10.2174/0929867323666151117121706. PMID26572612.
Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, et al. (June 2010). "Colchicine poisoning: the dark side of an ancient drug". Clinical Toxicology. 48 (5): 407–414. doi:10.3109/15563650.2010.495348. PMID20586571. S2CID33905426.
Drion N, Lemaire M, Lefauconnier JM, Scherrmann JM (October 1996). "Role of P-glycoprotein in the blood-brain transport of colchicine and vinblastine". J Neurochem. 67 (4): 1688–93. doi:10.1046/j.1471-4159.1996.67041688.x. PMID8858954. S2CID38446612.
Cisternino S, Rousselle C, Debray M, Scherrmann JM (October 2003). "In vivo saturation of the transport of vinblastine and colchicine by P-glycoprotein at the rat blood-brain barrier". Pharm Res. 20 (10): 1607–11. doi:10.1023/a:1026187301648. PMID14620515. S2CID10193442.
Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M (June 1987). "Does colchicine work? The results of the first controlled study in acute gout". Australian and New Zealand Journal of Medicine. 17 (3): 301–304. doi:10.1111/j.1445-5994.1987.tb01232.x. PMID3314832.
Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW (April 2010). "High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study". Arthritis and Rheumatism. 62 (4): 1060–1068. doi:10.1002/art.27327. PMID20131255. S2CID205424044.
Kesselheim AS, Solomon DH (June 2010). "Incentives for drug development--the curious case of colchicine". The New England Journal of Medicine. 362 (22): 2045–2047. doi:10.1056/NEJMp1003126. PMID20393164.
Sagorin C, Ertel NH, Wallace SL (March 1972). "Photoisomerization of colchicine. Loss of significant antimitotic activity in human lymphocytes". Arthritis and Rheumatism. 15 (2): 213–217. doi:10.1002/art.1780150213. PMID5027606.
Leete E (1963). "The biosynthesis of the alkaloids of Colchicum: The incorporation of phenylalaline-2-C14 into colchicine and demecolcine". J. Am. Chem. Soc. 85 (22): 3666–3669. doi:10.1021/ja00905a030.
Herbert RB (February 2001). "The biosynthesis of plant alkaloids and nitrogenous microbial metabolites". Natural Product Reports. 18 (1): 50–65. doi:10.1039/A809393H. PMID11245400.
British national formulary: BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 1085–1086. ISBN978-0-85711-338-2. "Colchicine". British national formulary. National Institute for Health and Care Excellence (NICE). Retrieved 26 January 2024. Available online in UK only
Nelson K, Fuster V, Ridker PM (August 2023). "Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease: JACC Review Topic of the Week". Journal of the American College of Cardiology. 82 (7): 648–660. doi:10.1016/j.jacc.2023.05.055. PMID37558377. S2CID260715494.
Cocco G, Chu DC, Pandolfi S (December 2010). "Colchicine in clinical medicine. A guide for internists". European Journal of Internal Medicine. 21 (6): 503–508. doi:10.1016/j.ejim.2010.09.010. PMID21111934.
Portincasa P (2016). "Colchicine, Biologic Agents and More for the Treatment of Familial Mediterranean Fever. The Old, the New, and the Rare". Current Medicinal Chemistry. 23 (1): 60–86. doi:10.2174/0929867323666151117121706. PMID26572612.
Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, et al. (June 2010). "Colchicine poisoning: the dark side of an ancient drug". Clinical Toxicology. 48 (5): 407–414. doi:10.3109/15563650.2010.495348. PMID20586571. S2CID33905426.
Drion N, Lemaire M, Lefauconnier JM, Scherrmann JM (October 1996). "Role of P-glycoprotein in the blood-brain transport of colchicine and vinblastine". J Neurochem. 67 (4): 1688–93. doi:10.1046/j.1471-4159.1996.67041688.x. PMID8858954. S2CID38446612.
Cisternino S, Rousselle C, Debray M, Scherrmann JM (October 2003). "In vivo saturation of the transport of vinblastine and colchicine by P-glycoprotein at the rat blood-brain barrier". Pharm Res. 20 (10): 1607–11. doi:10.1023/a:1026187301648. PMID14620515. S2CID10193442.
Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M (June 1987). "Does colchicine work? The results of the first controlled study in acute gout". Australian and New Zealand Journal of Medicine. 17 (3): 301–304. doi:10.1111/j.1445-5994.1987.tb01232.x. PMID3314832.
Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW (April 2010). "High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study". Arthritis and Rheumatism. 62 (4): 1060–1068. doi:10.1002/art.27327. PMID20131255. S2CID205424044.
Kesselheim AS, Solomon DH (June 2010). "Incentives for drug development--the curious case of colchicine". The New England Journal of Medicine. 362 (22): 2045–2047. doi:10.1056/NEJMp1003126. PMID20393164.
Sagorin C, Ertel NH, Wallace SL (March 1972). "Photoisomerization of colchicine. Loss of significant antimitotic activity in human lymphocytes". Arthritis and Rheumatism. 15 (2): 213–217. doi:10.1002/art.1780150213. PMID5027606.
Herbert RB (February 2001). "The biosynthesis of plant alkaloids and nitrogenous microbial metabolites". Natural Product Reports. 18 (1): 50–65. doi:10.1039/A809393H. PMID11245400.
Nelson K, Fuster V, Ridker PM (August 2023). "Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease: JACC Review Topic of the Week". Journal of the American College of Cardiology. 82 (7): 648–660. doi:10.1016/j.jacc.2023.05.055. PMID37558377. S2CID260715494.
Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, et al. (June 2010). "Colchicine poisoning: the dark side of an ancient drug". Clinical Toxicology. 48 (5): 407–414. doi:10.3109/15563650.2010.495348. PMID20586571. S2CID33905426.
Schwier NC, Cornelio CK, Boylan PM (April 2022). "A systematic review of the drug-drug interaction between statins and colchicine: Patient characteristics, etiologies, and clinical management strategies". Pharmacotherapy. 42 (4): 320–333. doi:10.1002/phar.2674. PMID35175631. S2CID246903117.
Drion N, Lemaire M, Lefauconnier JM, Scherrmann JM (October 1996). "Role of P-glycoprotein in the blood-brain transport of colchicine and vinblastine". J Neurochem. 67 (4): 1688–93. doi:10.1046/j.1471-4159.1996.67041688.x. PMID8858954. S2CID38446612.
Cisternino S, Rousselle C, Debray M, Scherrmann JM (October 2003). "In vivo saturation of the transport of vinblastine and colchicine by P-glycoprotein at the rat blood-brain barrier". Pharm Res. 20 (10): 1607–11. doi:10.1023/a:1026187301648. PMID14620515. S2CID10193442.
Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW (April 2010). "High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study". Arthritis and Rheumatism. 62 (4): 1060–1068. doi:10.1002/art.27327. PMID20131255. S2CID205424044.